Two new researches have been presented on the health day which supported two different diagnosis of prostate cancer. One advocates that an uncomplicated urine test could be helpful in picking out 50 percent men suffering from prostate cancer while the other is in the favor of combining the risk factors for prostate cancer to envisage the tendency of emerging the disease.

Digital rectal exam and PSA (prostate-specific antigen) are the modern methods to diagnose prostate cancer but they are of low specificity. So, a large number of results of prostate biopsies are turned out negative. There must be a better technique of testing to find out the best way of treatment for the men with aggressive prostate cancer and proper monitoring for those who have local or inactive cancer.

Keeping in view this factor a team of researchers has developed a test that can spot particular fusions of genes related to prostate cancer and applied the test on men with prostate cancer. TMPRSS2 gene and ERG gene are involved in these gene fusions which can be identified from a simple test of urine.

About 50 percent of men are found with the specific gene fusions. This urine test is well interrelated with the measures of determining the growth and intensity of prostate cancer.

Some researchers combined the PSA readings, the size of prostate, previous negative biopsy and the family history together to calculate the tendency of developing prostate cancer.